Advertisement
News
Subscribe to MDT Magazine News

Mucus: Fighting the war against pollutants

March 30, 2011 5:35 am | by EurekAlert | Comments

(American Friends of Tel Aviv University) New Tel Aviv University research has found that mucus, which was thought to protect our bodies against harmful pollutants, in fact may leave our bodies more vulnerable to them. But the discovery may prove useful in enabling some drugs to enter...

TOPICS:

Alexion gets board OK for stock 2-1 split

March 30, 2011 4:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Alexion Pharmaceuticals Inc. has won approval from its board of directors for a two-for-one stock split, which if approved by shareholders would double the number of issued common stock shares from 145 million to 290 million.

Biodel Announces Appointment of Dr. Brian J.G. Pereira as Board Chairman; Dr. Charles A. Sanders to Remain on Board

March 30, 2011 3:38 am | by Bio-Medicine.Org | Comments

DANBURY, Conn., March 30, 2011 /- Biodel Inc. (Nasdaq: BIOD ) announced today the appointment of Dr. Brian J.G. Pereira as board chairman effective immediately.  Dr. Pereira has served on the board since November 2007.  Dr. Charles A. Sanders, who served as chairman since March...

TOPICS:
Advertisement

Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes

March 30, 2011 3:38 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., March 30, 2011 /- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD with pegylated...

TOPICS:

Rx-webmasters.com is Your Number One Choice for Affordable Medications

March 30, 2011 3:37 am | by Bio-Medicine.Org | Comments

LONG ISLAND CITY, N.Y., March 30, 2011 /- Everyone knows where to look for the medications that you might have a need for one day. Online pharma shops have proven to be a reliable source for medication but how can you be sure that you are buying from the right generic Viagra merchant?...

TOPICS:

Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease

March 30, 2011 3:37 am | by Bio-Medicine.Org | Comments

OSAKA, Japan and NEW YORK, March 30, 2011 /- Dainippon Sumitomo Pharma Co, Ltd. (DSP) and Intercept Pharmaceuticals, Inc. (Intercept) today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR...

TOPICS:

Winner Medical CEO Awarded and Appointed Position by CNITA

March 30, 2011 3:37 am | by Bio-Medicine.Org | Comments

SHENZHEN, China, March 30, 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: WWIN ), ("Winner Medical") a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton® products in China, today announced that Mr....

TOPICS:

Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting

March 30, 2011 3:35 am | by Bio-Medicine.Org | Comments

SAN MATEO, Calif., March 30, 2011 /- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced the schedule of its upcoming cenderitide presentation taking place at the American College of Cardiology...

TOPICS:
Advertisement

Isis Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference

March 30, 2011 3:35 am | by Bio-Medicine.Org | Comments

CARLSBAD, Calif., March 30, 2011 /- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management will present a company overview at Needham's 10th Annual Healthcare Conference on Wednesday, April 06, 2011 at 10:40 a.m. ET at the New...

TOPICS:

Silence Therapeutics' Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting

March 29, 2011 10:33 pm | by Bio-Medicine.Org | Comments

LONDON, March 30, 2011 /- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have...

TOPICS:

Study: Emissions trading doesn't cause pollution 'hot spots'

March 29, 2011 9:38 pm | by EurekAlert | Comments

(Indiana University) Critics worry that trading emissions allowances will create heavily polluted "hot spots" in low-income and minority communities. But a new study from Indiana University finds the problem hasn't materialized.

TOPICS:

Lumileds launches its first high-voltage LED, using rectified AC

March 29, 2011 9:37 pm | by I-Micronews | Comments

Philips Lumileds of San Jose, CA, USA has expanded its LUXEON LED portfolio for the illumination market with its first high-voltage emitter.

II-VI expanding SiC operations in Mississippi

March 29, 2011 9:37 pm | by I-Micronews | Comments

The Wide Bandgap (WBG) materials division of II-VI Inc?s compound semiconductor business ? which is based in Pine Brook, NJ, USA ? says that it is expanding its operations, in two phases, at Mississippi State University?s (MSU?s) Research Park in Starkville, MS, in order to meet the...

<i>Patent Watch: </i>Gene patents flow into New England

March 29, 2011 8:34 pm | by Mass High Tech: The Journal of New England Technology | Comments

Suffolk Law School professor Kirk Teska: Gene patents are back in the news, so let's take a look at several gene related patents and published patent applications naming New England inventors of the last year.

TOPICS:

Healthspring offering raises $301 million

March 29, 2011 4:45 pm | by The Associated Press | Comments

Health insurer Healthspring Inc. said on Tuesday that it raised about $301 million under a share offering.The proceeds included money from a total of 8.625 million shares, including 1.125 million sold under an option for underwriters, which were re-sold at $35.95 per share.The company, which...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading